drugset
Drugs / SARS-CoV-2 VLP Vaccine
last change Dec 2021 re-read 3 minutes ago

SARS-CoV-2 VLP Vaccine

Vaccine

Developed for
COVID-19
Investigated by
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Ihsan GURSEL, PhD, Prof. · MonitorCRO · Nobel Pharmaceuticals · The Scientific and Technological Research Council of Turkey

Trials 1

today NCT04818281 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04818281 Mar → Dec 2021 COVID-19 Ihsan GURSEL, PhD, Prof. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SARS-CoV-2 VLP Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04818281 ↗
Modality Vaccine “VLP SARS-CoV-2 vaccine study” NCT04818281 ↗
Route Subcutaneous “All injections will be done subcutaneously.” NCT04818281 ↗